Cinarizine - instructions for use, dose, side effects, contraindications

Selective blocker slow calcium channels, reduces the entry of calcium ions into cells and reduces their content in the depot of the plasmolemma, lowers the tone of the smooth muscle arterioles.Immediately affecting the smooth muscles of blood vessels, reduces their response to nutrients (adrenaline, norepinephrine, dopamine, angiotensin, vasopressin). It has a vasodilating effect (especially with respect to cerebral vessels), without having a significant effect on blood pressure. It shows moderate antihistamine activity, reduces the excitability of the vestibular apparatus, lowers the tone of the sympathetic nervous system. Increases the elasticity of erythrocyte membranes, their ability to deform, reduces the viscosity of the blood. Increases muscle resistance to hypoxia.

Pharmacokinetics:

Absorbed in the stomach and intestines. The maximum concentration in the blood plasma after oral administration after 1-3 hours. The connection with plasma proteins is 91%. It is completely metabolized in the liver (via glucuronation). The half-life is 4 hours. It is excreted in the form of metabolites: 1/3 - kidneys and 2/3 - with fecal masses.

Indications:

symptoms of cerebrovascular insufficiency (dizziness, tinnitus, headache, memory impairment, decreased concentration of attention);
vestibular disorders (incl.Meniere's disease; dizziness, tinnitus, nystagmus, nausea and vomiting of a labyrinthine origin);
prevention of kinetosis ("road sickness" - sea and air sickness);
violations of peripheral circulation: Raynaud's disease, "intermittent" lameness, acrocyanosis, trophic disorders (including trophic and varicose ulcers).

Contraindications:

Hypersensitivity and / or intolerance of substances that make up the drug; pregnancy, lactation, children under 16; lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome; patients with celiac disease (gluten enteropathy).

Carefully:

With Parkinson's disease.

Dosing and Administration:

Inside, after eating.

With insufficiency of cerebral circulation: 25 mg three times a day.

If peripheral circulation is disturbed, 50-75 mg three times a day.

With vestibular disorders - 25 mg three times a day.

The maximum recommended dose should not exceed 225 mg (9 tablets) per day. The course of treatment is from several weeks to several months.

With kinetosis ("road" disease): 25 mg for half an hour before the road (if necessary, repeated intake of 25 mg after 6 hours).

The drug is used in children from 16 years with regard to dosing for adults.

Side effects:

From the nervous system: drowsiness, fatigue, headache, extrapyramidal disorders (tremor of limbs and increased muscle tone, hypokinesia), depression.

From the digestive system: dry mouth, pain in the epigastric region, dyspepsia, cholestatic jaundice.

From the skin: sweating, red flat lichen (extremely rare), skin rash.

Other: allergic reactions, weight gain, lupus-like syndrome, lowering blood pressure.

Overdose:

Symptoms: increased severity of side effects, lower blood pressure, vomiting, coma.

Treatment: there is no specific antidote, gastric lavage, activated charcoal, symptomatic therapy.

Interaction:

Strengthens the inhibitory effect on the central nervous system of ethanol, sedatives, tricyclic antidepressants.

With simultaneous application cinnarizine enhances the effects of nootropic, antihypertensive and vasodilating agents.

Special instructions:

Patients with Parkinson's disease, the drug is prescribed only in cases when the benefits of cinnarizine treatment outweigh the possible worsening of the course of the underlying disease.

With prolonged use, it is recommended that a control laboratory examination of the liver, kidneys, and peripheral blood is recommended.

In connection with the antihistamine effect, the appointment of cinnarizine should be discontinued 4 days before the allergic skin test.

Cinnarizine can affect the result in the case of anti-doping control of athletes (false positive result).

Patients with intolerance to lactose, should consider its content as an auxiliary substance.

The drug contains wheat starch and is therefore not recommended for patients with celiac disease (gluten enteropathy).

Effect on the ability to drive transp. cf. and fur:

It is possible to develop drowsiness, especially at the beginning of treatment, therefore, care should be taken when driving vehicles and engaging in other potentially hazardous activities requiring increased concentration and speed of psychomotor reactions.

Form release / dosage:

Tablets 25 mg.

Packaging:

10 tablets in a blister made of polyvinylchloride film and aluminum foil. 5 blisters with instructions for use in a cardboard pack.

50 tablets in a blister made of polyvinylchloride film and aluminum foil.1 blister with instructions for use in a cardboard bundle.

Storage conditions:

In a dry, the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children!

Shelf life:3 years. Do not use after expiry date.

Terms of leave from pharmacies:On prescription

Registration number:П N015269 / 01

Date of registration:11.08.2008

The owner of the registration certificate:Balkanfarma - Dupnitsa ADBalkanfarma - Dupnitsa AD Bulgaria

Manufacturer: & nbsp

BALKANPHARMA-DUPNITSA, AD Bulgaria

Representation: & nbspAktavis, Open Company Aktavis, Open Company

Information update date: & nbsp09.10.2015

Illustrated instructions

Instructions

Cinnarizine (Cinnarizine)